A Study of 2 Different Formulations of Insulin Lispro in Healthy Participants

Evaluation of the Bioequivalence of Two Formulations of Insulin Lispro in Healthy Subjects

The study involves 4 injections of insulin lispro and its purpose is to:

• Determine if 2 formulations of insulin lispro are treated by the body in a similar way.
• Compare how the 2 formulations of insulin lispro affect blood sugar level.
• Determine the safety of each insulin lispro formulations and any side effects that might be associated with them when given to healthy participants. The study is expected to last up to approximately 9 weeks for each participant.

Inclusion Criteria:

• Are healthy males or females
• Body mass index (BMI) between 18.5 and 29.9 kilogram per meter squared (kg/m^2)
• Are nonsmokers
• Have normal blood pressure and pulse rate, a normal electrocardiogram (ECG), and clinical laboratory test results within normal reference range at screening.

Exclusion Criteria:

• History of first-degree relatives known to have diabetes mellitus
• Evidence of significant active neuropsychiatric disease
• Evidence of an acute infection with fever or infectious disease
• Intend to use over-the-counter or prescription medication (apart from vitamin/mineral supplements, occasional paracetamol, or birth control methods).
• Have used systemic glucocorticoids within 3 months prior to entry into the study.
• Have donated blood of 1 unit or more within the last 3 months prior to study entry
• Excessive alcohol intake
• Have a fasting venous blood glucose (fasting blood glucose [FBG], plasma) >6 millimoles per liter (mmol/L) at screening
• Have positive hepatitis B surface antigen.